At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 60 enrolled
Drug / intervention
Escitalopram +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Study of Neural Responses Induced by Simulated Antidepressants
In Brief
A Phase 3 clinical trial evaluating Escitalopram, Placebo, and 1 other intervention for Major Depressive Disorder. Completed, enrolled 60 participants across 1 site.
Detailed Summary
The proposed work aims to examine the neural changes associated with fast-acting antidepressant treatments in order to develop imaging-based biomarkers of treatment response for depression.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMajor Depressive Disorder
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20162017201820192020202120222023202420252026
First PostedFeb 2016
Enrollment StartSep 2016
Primary CompletionMay 2021
TodayJul 2026
First PostedFeb 4, 2016
Enrollment StartSep 1, 2016
Primary CompletionMay 1, 2021
TodayJul 2, 2026
Enrollment to primary: 4.7 yearsPosted 10.4 years ago
Interventions
Escitalopramdrug
Selective Serotonin Reuptake Inhibitor (SSRI)
Placebodrug
Placebo
Real-time Neurofeedback fMRI task pre- and post-RCTbehavioral
Placebo experiment during an fMRI scanning session